News Sentiment

GLUE sentiment intelligence

Monte Rosa Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.04 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-4.8% over one week, +26.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -4.8% Price reacting lower
Trend fit Trend active 26.4% over four weeks
Fair value 167.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 38
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
simplywall.st 6
Market source 5
MarketBeat 4
Investing.com Canada 3
GlobeNewswire 3
Simply Wall Street 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 14
Analyst action 4
Deals and strategy 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Stock Titan Direct company coverage

GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise

Jennifer Champoux, a security holder of Monte Rosa Therapeutics (NASDAQ: GLUE), plans to sell 4,351 shares of common stock with an aggregate market value of $101,729.86. This sale, facilitated through UBS Financial Services on NASDAQ, is linked to a cash-funded exercise of stock

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:40
Source
Stock Titan
Stock Traders Daily Direct company coverage

Trading Systems Reacting to (GLUE) Volatility

This article analyzes Monte Rosa Therapeutics Inc. (NASDAQ: GLUE), highlighting weak near-term sentiment but strong mid and long-term outlook. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal

Tone
Positive 73/100
Event
Guidance
Published
15 Jul 2026 10:20
Source
Stock Traders Daily
The Globe and Mail Direct company coverage

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

Two healthcare stocks, Monte Rosa Therapeutics (GLUE) and Neurocrine (NBIX), have received bullish sentiments from analysts. Guggenheim analyst Michael Schmidt reiterated a Buy rating for Monte Rosa Therapeutics with a $35.00 price target, while Wedbush analyst Laura Chico mainta

Tone
Positive 85/100
Event
Analyst action
Published
14 Jul 2026 11:17
Source
The Globe and Mail
MarketBeat Direct company coverage

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened

Monte Rosa Therapeutics (NASDAQ:GLUE) experienced an 8.7% stock price drop on Friday, trading as low as $22.90 on unusually low volume. This downturn follows mixed analyst ratings, with several firms cutting targets, and the company missing its last earnings and revenue expectati

Tone
Negative 14/100
Event
Earnings
Published
10 Jul 2026 16:40
Source
MarketBeat
Simply Wall Street Direct company coverage

Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build

Monte Rosa Therapeutics (GLUE) has been reclassified into growth indexes such as Russell growth benchmarks, following a significant surge in its share price. While the stock's Price-to-Sales (P/S) ratio of 47.3x suggests it is overvalued compared to industry averages and an estim

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:02
Source
Simply Wall Street
Investing.com Canada Direct company coverage

Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Monte Rosa Therapeutics Inc. for July 7th. It briefly mentions the document and offers options to view comments, but provides no further details about the filing's content. The rest of the page consists of general fin

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:11
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com

Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, sold 6,000 shares of common stock for approximately $139,849 after exercising stock options. The sale occurred when the stock was near its 52-week high, and an InvestingPro analysis suggests the shares are overv

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:11
Source
Investing.com Canada
Stock Titan Direct company coverage

Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise

Monte Rosa Therapeutics' Chief Scientific Officer, Sharon Townson, reported an exercise-and-sell transaction involving company stock. She exercised options for 6,000 shares at $6.14 each and subsequently sold all 6,000 shares, including 400 at $24.13 and the remainder at a weight

Tone
Negative 39/100
Event
Market update
Published
07 Jul 2026 21:11
Source
Stock Titan
Investing.com Direct company coverage

Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849

Monte Rosa Therapeutics CSO Sharon Townson sold 6,000 shares of company stock for approximately $139,849 on July 6, 2026, following the exercise of stock options. The sales were conducted under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:39
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com

This article announces the filing of a Form 4 for Monte Rosa Therapeutics Inc. on July 6th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by insiders. The brief content provides the headline and mentions Monte Rosa Therapeutics Inc.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:09
Source
Investing.com Canada
Stock Titan Direct company coverage

NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales

New Enterprise Associates (NEA) has updated its ownership in Monte Rosa Therapeutics (GLUE) through a Schedule 13D/A filing. NEA 17, a part of NEA, now holds 6,692,298 shares, representing 7.9% of Monte Rosa's outstanding common stock. This adjustment includes a pro rata distribu

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 03:09
Source
Stock Titan
Stock Titan Direct company coverage

NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE)

NEA-affiliated funds restructured their holdings in Monte Rosa Therapeutics (NASDAQ: GLUE) through a series of internal distributions, not open-market transactions. New Enterprise Associates 17, L.P. distributed 1,000,000 shares pro rata to its partners, and NEA Partners 17 subse

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:09
Source
Stock Titan
Finviz Direct company coverage

GLUE - Monte Rosa Therapeutics Inc Volatility & Greeks

This article provides detailed financial and performance data for Monte Rosa Therapeutics Inc. (GLUE), including its volatility, options Greeks, market capitalization, earnings per share, sales figures, and insider ownership statistics. It also highlights the stock's price perfor

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 08:09
Source
Finviz
MarketBeat Direct company coverage

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages

Nine brokerages have given Monte Rosa Therapeutics (NASDAQ:GLUE) an average recommendation of "Moderate Buy," with an average 12-month price target of $33.33. Recent analyst target adjustments have been mixed, with some increases and some decreases. Despite recent insider selling

Tone
Neutral 50/100
Event
Analyst action
Published
05 Jul 2026 12:10
Source
MarketBeat
Sahm Direct company coverage

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics, Inc. announced inducement equity awards to three new non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include non-qualified stock options for 18,025 shares and restricted stock units for 3,900 shares, both vesting over

Tone
Positive 64/100
Event
Market update
Published
04 Jul 2026 02:40
Source
Sahm
Stock Titan Direct company coverage

Monte Rosa lures 3 new hires with stock awards worth 18,025 options

Monte Rosa Therapeutics (Nasdaq: GLUE) has granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 18,025 shares at an exercise price of $24.02 and 3,

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:12
Source
Stock Titan
Investing.com Direct company coverage

Monte Rosa CMO Filip Janku sells $132k in company stock

Monte Rosa Therapeutics CMO Filip Janku sold 5,407 shares of company stock for $132,471 under a pre-arranged trading plan, while simultaneously acquiring the same number of shares by exercising stock options. The sale occurred near the stock's 52-week high after a 425% gain in th

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 13:12
Source
Investing.com
MarketBeat Direct company coverage

Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Filip Janku, an insider at Monte Rosa Therapeutics (NASDAQ:GLUE), sold 5,407 shares of the company's stock for approximately $132,472, reducing his ownership by 8.19%. This sale, along with several others in June, occurred as GLUE shares traded near their 52-week high, despite th

Tone
Negative 40/100
Event
Market update
Published
01 Jul 2026 21:40
Source
MarketBeat
Stock Titan Direct company coverage

Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan

Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, exercised stock options for 5,407 shares at $13.41 per share and subsequently sold them at $24.50 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 4, 2026.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com

This article reports on the filing of Form 4 by Monte Rosa Therapeutics Inc. for the period ending June 30. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade their company's stock. The article mentio

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 13:39
Source
Investing.com Nigeria
Moomoo Direct company coverage

Monte Rosa Therapeutics Price Target Raised to $35.00/Share From $30.00 by Guggenheim

Guggenheim has increased its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) from $30.00 to $35.00 per share. This adjustment suggests a positive outlook on the company's future performance. However, the report does not provide details on the reasons behind the target rais

Tone
Positive 73/100
Event
Analyst action
Published
01 Jul 2026 02:40
Source
Moomoo
Investing.com Nigeria Direct company coverage

Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com

Investing.com has published a Form 144 filing for Monte Rosa Therapeutics as of June 30th. This brief article primarily lists market data for various indices, commodities, bonds, and shares, along with trending stocks and popular news articles from Investing.com. The information

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 23:16
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares

Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, executed an exercise-and-sell transaction, acquiring 6,000 shares at $7.56 per share through stock options and simultaneously selling them at $22.95 per share. These transactions, totaling $137,700 from the sale, were c

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11

Monte Rosa Therapeutics director Anthony M. Manning exercised stock options to acquire 10,000 shares of common stock at $4.16 per share, then immediately sold all 10,000 shares at $23.11 per share in an open-market transaction. Following these transactions, Manning holds 0 direct

Tone
Negative 41/100
Event
Market update
Published
30 Jun 2026 19:39
Source
Stock Titan
Simply Wall Street Direct company coverage

Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?

Monte Rosa Therapeutics (GLUE) has been added to several Russell growth indexes following strong recent stock performance, including a 429.93% return over one year. The company is currently unprofitable and trades at a high price-to-sales (P/S) ratio of 47x, significantly above i

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 07:10
Source
Simply Wall Street
Stock Titan Direct company coverage

GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares

Monte Rosa Therapeutics (NASDAQ: GLUE) insider filed a Form 144, disclosing the exercise of 6,000 stock options and subsequent 10b5-1 sales totaling 41,845 shares. These sales, executed on June 23 and June 24, 2026, generated total proceeds of $882,203.50. This routine transactio

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:10
Source
Stock Titan